Market Overview - On August 26, the AI medical sector experienced a slight decline of 0.01%, with Bei Rui Gene leading the losses [1] - The Shanghai Composite Index closed at 3868.38, down 0.39%, while the Shenzhen Component Index closed at 12473.17, up 0.26% [1] Stock Performance - Notable gainers in the AI medical sector included: - Saily Medical (603716) with a closing price of 36.40, up 4.99% and a trading volume of 707,500 shares, totaling 2.592 billion yuan [1] - Sichuang Medical (300078) closed at 3.80, up 2.98% with a trading volume of 666,200 shares, totaling 250 million yuan [1] - Jiahe Meikang (688246) closed at 38.21, up 2.00% with a trading volume of 56,600 shares, totaling 215 million yuan [1] - Major decliners included: - Bei Rui Gene (000710) closed at 15.94, down 4.03% with a trading volume of 609,700 shares, totaling 977 million yuan [2] - Yao Shi Technology (300725) closed at 45.18, down 3.91% with a trading volume of 165,300 shares, totaling 756 million yuan [2] - Anbiping (688393) closed at 31.66, down 3.21% with a trading volume of 40,200 shares, totaling 129 million yuan [2] Capital Flow - The AI medical sector saw a net outflow of 707 million yuan from institutional investors, while retail investors experienced a net inflow of 697 million yuan [2] - The table of capital flow indicates that: - Wei Ning Health (300253) had a net inflow of 75.39 million yuan from institutional investors [3] - Zhejiang Data Culture (600633) had a net inflow of 67.70 million yuan from institutional investors [3] - Huada Gene (300676) had a net inflow of 23.14 million yuan from institutional investors [3]

Core Viewpoint - The collaboration between Chengdu Berry Genomics Co., Ltd. and its partners aims to drive innovation in medical technology and industry upgrades through digital assetization, exploring RWA applications to reshape the global gene diagnostic asset value chain and maximize asset value [1][2]. Group 1: Company Overview - Berry Genomics focuses on technological innovation to advance precision medicine, utilizing high-throughput sequencing technology to create solutions across various fields, including reproductive health and genetic disease testing [2]. - The company has pioneered the clinical transformation of third-generation HiFi sequencing technology and has successfully launched multiple products, establishing a strong technological moat [2]. Group 2: Collaboration Details - The partners plan to use the stable revenue from Berry Genomics' third-generation HiFi sequencing production line and the technical service income from the GENOisi™ intelligent system as underlying assets for digital rights exploration and RWA tokenization [4]. - The project aims to quantify the value of the GENOisi™ intelligent system as a new type of digital asset, accelerating the integration of technology and capital, thereby injecting new momentum into the sustainable development of precision medicine [4]. Group 3: Future Directions - This collaboration represents a critical step in the digitalization of healthcare assets, standardizing data rights in the medical health sector and enhancing the quantification and circulation of new digital assets like AI intelligent systems [5]. - The company intends to deepen technical and resource collaboration with partners, actively exploring more digital paths for medical assets, contributing to the popularization of precision medicine, data value extraction, and the upgrade of the global healthcare ecosystem [5].

Market Performance - On August 22, the medical services sector rose by 1.29%, with Berry Genomics leading the gains [1] - The Shanghai Composite Index closed at 3825.76, up 1.45%, while the Shenzhen Component Index closed at 12166.06, up 2.07% [1] Top Gainers in Medical Services - Berry Genomics (000710) closed at 15.79, up 10.03% with a trading volume of 749,900 shares and a turnover of 1.153 billion yuan [1] - Haochen Medical (002622) closed at 4.21, up 9.92% with a trading volume of 1.4424 million shares and a turnover of 585 million yuan [1] - Golden Domain Medical (603882) closed at 11, up 4.02% with a trading volume of 148,600 shares and a turnover of 461 million yuan [1] Top Losers in Medical Services - Boji Pharmaceutical (300404) closed at 11.37, down 5.09% with a trading volume of 490,800 shares and a turnover of 557 million yuan [2] - ST Shenghua (000504) closed at 9.79, down 3.83% with a trading volume of 85,800 shares and a turnover of 84.73 million yuan [2] - Chengda Pharmaceutical (301201) closed at 30.34, down 3.38% with a trading volume of 104,000 shares and a turnover of 320 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 153 million yuan from institutional investors, while retail investors saw a net inflow of 246 million yuan [2][3] - Berry Genomics had a net inflow of 468 million yuan from institutional investors, but a net outflow of 214 million yuan from speculative funds [3] - Haochen Medical saw a net inflow of 116 million yuan from institutional investors, with a net outflow of 82.73 million yuan from speculative funds [3]

Market Overview - The Shanghai Composite Index closed at 3825.76 points, above the five-day moving average, with an increase of 1.45% [1] - The total trading volume of A-shares reached 25,788.42 billion yuan [1] Stocks Performance - A total of 575 A-shares broke through the five-day moving average today [1] - Stocks with significant deviation rates include: - Aibulu (301259) with a deviation rate of 15.39% and a daily increase of 19.99% [1] - Sanchuan Wisdom (300066) with a deviation rate of 13.32% and a daily increase of 20.06% [1] - Pinggao Co. (688227) with a deviation rate of 13.23% and a daily increase of 19.99% [1] - Other notable stocks with smaller deviation rates include: - Weihede (small deviation rate) just above the five-day moving average [1] - Kaige Precision Machinery (small deviation rate) just above the five-day moving average [1] - Hanlan Environment (small deviation rate) just above the five-day moving average [1]

Group 1 - The company, Berry Genomics, announced that its wholly-owned subsidiary, Hangzhou Berry Health and康基因诊断技术有限公司, applied for a comprehensive credit line of 40 million yuan from Hangzhou United Rural Commercial Bank [1] - The credit line has a term of one year, and the company agreed to provide joint liability guarantee for the debt incurred from this credit line [1] - As of the announcement date, the total amount of external guarantees provided by the company and its subsidiaries is 357 million yuan, which accounts for 21.26% of the company's most recent audited net assets [1]

（文章来源：证券日报） 证券日报网讯 8月20日晚间，贝瑞基因发布公告称，公司第十届董事会第十六次会议审议通过了《关于 为全资子公司提供担保的议案》。 ...

Core Viewpoint - The company, Beirui Gene, is seeking a credit facility of 40 million yuan for its wholly-owned subsidiary, Hangzhou Beirui, to support its operations and ensure stable development [1][2]. Financial Overview - As of March, Hangzhou Beirui reported total assets of 1.106 billion yuan, total liabilities of 266 million yuan, and net assets of 840 million yuan [2]. - In the first quarter, Hangzhou Beirui's unaudited revenue and net profit were 90.06 million yuan and 4.49 million yuan, respectively [2]. - The total amount of external guarantees provided by Beirui Gene and its subsidiaries is 357 million yuan, which is 21.26% of the latest audited net assets [2]. Performance Challenges - Beirui Gene has faced continuous performance pressure since 2021, with revenues declining from 1.422 billion yuan in 2021 to an expected 1.078 billion yuan in 2024, and net profits turning negative [4]. - The company anticipates a net loss of 22 million to 33 million yuan in the first half of 2025, compared to a profit of 9.26 million yuan in the same period last year [4]. Market Position and Future Plans - The company focuses on the reproductive health sector, with significant commercial success in prenatal testing, while the prenatal and newborn markets are still in the early stages [5]. - Beirui Gene plans to leverage artificial intelligence and its advanced sequencing technology to expand into more complex genetic testing services and provide direct health services to consumers [5].

（文章来源：每日经济新闻） 2024年1至12月份，贝瑞基因的营业收入构成为：基因检测行业占比100.0%。 贝瑞基因（SZ 000710，收盘价：14.52元）8月20日晚间发布公告称，公司第十届第十六次董事会会议 于2025年8月20日在北京市昌平区生命园路4号院5号楼8层会议室以现场与通讯会议相结合的方式召开。 会议审议了《关于为全资子公司提供担保的议案》等文件。 ...

2024年1至12月份，贝瑞基因的营业收入构成为：基因检测行业占比100.0%。 （文章来源：每日经济新闻） 贝瑞基因（SZ 000710，收盘价：14.52元）8月20日晚间发布公告称，近日，公司全资子公司杭州贝瑞 向杭州联合农村商业银行股份有限公司高沙支行申请综合授信4000万元，授信期限1年。公司同意为杭 州贝瑞使用上述授信所形成的债务提供连带责任保证担保。 截至本公告日，公司及控股子公司对外担保总额为人民币3.57亿元，占公司最近一期经审计净资产比例 为21.26%；其中公司及其控股子公司对合并报表外单位提供的担保总余额为1.47亿元，占公司最近一期 经审计净资产的比例为8.75%。 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-042 成都市贝瑞和康基因技术股份有限公司 关于为全资子公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 近日，成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基 因""公司"）之全资子公司杭州贝瑞和康基因诊断技术有限公司（以下简称 "杭州贝瑞"）向杭州联合农村商业银行股份有限公司高沙支行申请综合授信 4,000 万元，授信期限 1 年。公司同意为杭州贝瑞使用上述授信所形成的债务 提供连带责任保证担保。 公司于 2025 年 8 月 20 日召开第十届董事会第十六次会议审议通过了《关 于为全资子公司提供担保的议案》。根据中国证监会《上市公司监管指引第 8 号—上市公司资金往来、对外担保的监管要求》《深圳证券交易所股票上市规 则》《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》 《公司章程》等有关规定，本次担保无需提交股东大会审议，董事会审议通过 后方可实施。董事会授权公司总经理根据杭州贝瑞实际日常经营资金需求办理 担保事宜并签署相关文件， ...